Observing real-world care of patients with transthyretin amyloidosis
Follows adults with ATTR amyloidosis, a rare protein-build-up disease, and their treatments over time.
Plain-language title generated from the registry record
Registry title: Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Key facts
- Where
- Halifax, London, Montreal, Rimouski, Toronto, and Vancouver, CanadaSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 130 years old?
Source: NCT06465810, who can take part
Where in Canada
- HalifaxHalifax, CanadaTaking people
- LondonLondon, CanadaTaking people
- MontrealMontreal, CanadaNot yet recruiting
- RimouskiRimouski, CanadaNot yet recruiting
- TorontoToronto, CanadaTaking people
- VancouverVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06465810
- Record updated
- 23 September 2026
- Original description
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.Read full original descriptionShow less
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Inclusion: Patient willing and able to provide written informed consent to participate in the study; Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis; Aged ≥18 years at the time of signing the informed consent; Patient willing and able to participate in collection of electronic patient reported outcomes (PROs).
Exclusion: Concurrent participation in any interventional trial for ATTR amyloidosis; Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA); Involvement in the planning and/or conduct of the current study; Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers.